Identification of six novel P450 oxidoreductase missense variants in Ashkenazi and Moroccan Jewish populations

Pharmacogenomics

Volumn 13, Issue 5, 2012, Pages 543-554

  Tomkov, Mria ^a   Marohnic, Christopher C ^b   Gurwitz, David ^c   Eda, Ondaej ^a   Masters, Bettie Sue Siler ^b   Martsek, Pavel ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b Mays Cancer Center at UT Health San Antonio   (United States)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

allele frequencies; CYP oxidoreductase; haplotype; Jewish populations; pharmacogenetics; POR

Indexed keywords

CYTOCHROME P450 REDUCTASE;

A115V GENE; ALLELE; ARTICLE; ASHKENAZI JEWISH; CONTROLLED STUDY; CRYSTAL STRUCTURE; D344N GENE; D648N GENE; DNA POLYMORPHISM; DNA SEQUENCE; E398A GENE; ENZYME ACTIVITY; ENZYME ANALYSIS; ETHNIC DIFFERENCE; ETHNIC GROUP; FEMALE; GENE; GENE FREQUENCY; GENE IDENTIFICATION; GENE LOCATION; GENETIC CODE; GENETIC MARKER; GENETIC VARIABILITY; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; MALE; MISSENSE MUTATION; MOROCCAN JEWISH; NORMAL HUMAN; NUCLEOTIDE SEQUENCE; P228L GENE; PHARMACOGENETICS; POPULATION RESEARCH; POR GENE; S102P GENE; S400S GENE; SINGLE NUCLEOTIDE POLYMORPHISM; T29T GENE; V164M GENE; V191M GENE; V631I GENE; Y143Y GENE; Y248Y GENE;

FEMALE; GENE FREQUENCY; GENETIC MARKERS; HAPLOTYPES; HUMANS; ISRAEL; JEWS; LINKAGE DISEQUILIBRIUM; MALE; MODELS, MOLECULAR; MOROCCO; MUTATION, MISSENSE; NADPH-FERRIHEMOPROTEIN REDUCTASE; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; SEQUENCE ANALYSIS, DNA;

EID: 84859251297     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.12.21     Document Type: Article

References (54)

1. Masters BS. The journey from NADPHcytochrome P450 oxidoreductase to nitric oxide synthases. Biochem. Biophys. Res. Commun. 338(1), 507-519 (2005). (Pubitemid 41540597)
2. Shephard EA, Phillips IR, Santisteban I et al. Isolation of a human cytochrome P-450 reductase cDNA clone and localization of the corresponding gene to chromosome 7q11.2. Ann. Hum. Genet. 53(Pt 4), 291-301 (1989). (Pubitemid 19282102)
3. Scott RR, Gomes LG, Huang N, Van Vliet G, Miller WL. Apparent manifesting heterozygosity in P450 oxidoreductase deficiency and its effect on coexisting 21-hydroxylase deficiency. J. Clin. Endocrinol. Metab. 92(6), 2318-2322 (2007). (Pubitemid 46997140)
4. Wang M, Roberts DL, Paschke R, Shea TM, Masters BS, Kim JJ. Three-dimensional structure of NADPH-cytochrome P450 reductase: prototype for FMN- and FAD-containing enzymes. Proc. Natl Acad. Sci. USA 94(16), 8411-8416 (1997). (Pubitemid 27335052)
5. Black SD, French JS, Williams CH Jr, Coon MJ. Role of a hydrophobic polypeptide in the N-terminal region of NADPH-cytochrome P-450 reductase in complex formation with P-450LM. Biochem. Biophys. Res. Commun. 91(4), 1528-1535 (1979).
6. Xia C, Panda SP, Marohnic CC, Martasek P, Masters BS, Kim JJ. Structural basis for human NADPH-cytochrome P450 oxidoreductase deficiency. Proc. Natl Acad. Sci. USA 108(33), 13486-13491 (2011).
7. Adachi M, Tachibana K, Asakura Y, Yamamoto T, Hanaki K, Oka A. Compound heterozygous mutations of cytochrome P450 oxidoreductase gene (POR) in two patients with Antley-Bixler syndrome. Am. J. Med. Genet. A 128A(4), 333-339 (2004). (Pubitemid 38988634)
8. Arlt W, Walker EA, Draper N et al. Congenital adrenal hyperplasia caused by mutant P450 oxidoreductase and human androgen synthesis: analytical study. Lancet 363(9427), 2128-2135 (2004). (Pubitemid 38844154)
9. Fluck CE, Tajima T, Pandey AV et al. Mutant P450 oxidoreductase causes disordered steroidogenesis with and without Antley-Bixler syndrome. Nat. Genet. 36(3), 228-230 (2004). (Pubitemid 38282745)
10. Fukami M, Horikawa R, Nagai T et al. Cytochrome P450 oxidoreductase gene mutations and Antley-Bixler syndrome with abnormal genitalia and/or impaired steroidogenesis: molecular and clinical studies in 10 patients. J. Clin. Endocrinol. Metab. 90(1), 414-426 (2005). (Pubitemid 40116690)
11. Huang N, Pandey AV, Agrawal V et al. Diversity and function of mutations in P450 oxidoreductase in patients with Antley-Bixler syndrome and disordered steroidogenesis. Am. J. Hum. Genet. 76(5), 729-749 (2005). (Pubitemid 40563096)
12. Hart SN, Wang S, Nakamoto K, Wesselman C, Li Y, Zhong XB. Genetic polymorphisms in cytochrome P450 oxidoreductase influence microsomal P450-catalyzed drug metabolism. Pharmacogenet. Genomics 18(1), 11-24 (2008). (Pubitemid 351161645)
13. Huang N, Agrawal V, Giacomini KM, Miller WL. Genetics of P450 oxidoreductase: sequence variation in 842 individuals of four ethnicities and activities of 15 missense mutations. Proc. Natl Acad. Sci. USA 105(5), 1733-1738 (2008). (Pubitemid 351346583)
14. Saito Y, Yamamoto N, Katori N et al. Genetic polymorphisms and haplotypes of POR, encoding cytochrome P450 oxidoreductase, in a Japanese population. Drug Metab. Pharmacokinet. 26(1), 107-116 (2011).
15. Fluck CE, Mallet D, Hofer G et al. Deletion of P399-E401 in NADPH cytochrome P450 oxidoreductase results in partial mixed oxidase deficiency. Biochem. Biophys. Res. Commun. 412(4), 572-577 (2011).
16. Shen AL, O'Leary KA, Kasper CB. Association of multiple developmental defects and embryonic lethality with loss of microsomal NADPH-cytochrome P450 oxidoreductase. J. Biol. Chem. 277(8), 6536-6541 (2002). (Pubitemid 34968452)
17. Ribes V, Otto DM, Dickmann L et al. Rescue of cytochrome P450 oxidoreductase (Por) mouse mutants reveals functions in vasculogenesis, brain and limb patterning linked to retinoic acid homeostasis. Dev. Biol. 303(1), 66-81 (2007).
18. Henderson CJ, Otto DM, Carrie D et al. Inactivation of the hepatic cytochrome P450 system by conditional deletion of hepatic cytochrome P450 reductase. J. Biol. Chem. 278(15), 13480-13486 (2003). (Pubitemid 36800122)
19. Feidt DM, Klein K, Nussler A, Zanger UM. RNA-interference approach to study functions of NADPH: cytochrome P450 oxidoreductase in human hepatocytes. Chem. Biodivers. 6(11), 2084-2091 (2009).
20. Antley R, Bixler D. Trapezoidocephaly, midfacial hypoplasia and cartilage abnormalities with multiple synostoses and skeletal fractures. Birth Defects Orig. Artic. Ser. 11(2), 397-401 (1975).
21. Bertz RJ, Granneman GR. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin. Pharmacokinet. 32(3), 210-258 (1997). (Pubitemid 27122521)
22. Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286(5439), 487-491 (1999).
23. Gomes AM, Winter S, Klein K et al. Pharmacogenomics of human liver cytochrome P450 oxidoreductase: multifactorial analysis and impact on microsomal drug oxidation. Pharmacogenomics 10(4), 579-599 (2009).
24. Need AC, Goldstein DB. Next generation disparities in human genomics: concerns and remedies. Trends Genet. 25(11), 489-494 (2009).
25. Gurwitz D, Lunshof JE. Personalized pharmacotherapy: genotypes, biomarkers, and beyond. Clin. Pharmacol. Ther. 85(2), 142 (2009).
26. Gurwitz D, Kimchy O, Bonne-Tamir B. The Israeli DNA and cell line collection: a human diversity repository. In: Populations and Genetics. Legal and Socio-Ethical Perspectives. Martinus Nijhoff, Leiden, The Netherlands (2003)
27. Ulbrichova-Douderova D, Martasek P. Detection of DNA variations in the polymorphic hydroxymethylbilane synthase gene by high-resolution melting analysis. Anal. Biochem. 395(1), 41-48 (2009).
28. Kimmel G, Shamir R. GERBIL: genotype resolution and block identification using likelihood. Proc. Natl Acad. Sci. USA 102(1), 158-162 (2005). (Pubitemid 40094445)
29. Davidovich O, Kimmel G, Shamir R. GEVALT: an integrated software tool for genotype analysis. BMC Bioinformatics 8, 36 (2007).
30. Eichelbaum M, Ingelman-Sundberg M, Evans WE. Pharmacogenomics and individualized drug therapy. Annu. Rev. Med. 57, 119-137 (2006). (Pubitemid 43261982)
31. Budnitz DS, Pollock DA, Weidenbach KN, Mendelsohn AB, Schroeder TJ, Annest JL. National surveillance of emergency department visits for outpatient adverse drug events. JAMA 296(15), 1858-1866 (2006). (Pubitemid 44596195)
32. Woodcock J, Lesko LJ. Pharmacogenetics - tailoring treatment for the outliers. N. Engl. J. Med. 360(8), 811-813 (2009).
33. Zanger UM, Turpeinen M, Klein K, Schwab M. Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Anal. Bioanal. Chem. 392(6), 1093-1108 (2008).
34. Behar DM, Metspalu E, Kivisild T et al. Counting the founders: the matrilineal genetic ancestry of the Jewish diaspora. PLoS ONE 3(4), e2062 (2008).
35. Behar DM, Yunusbayev B, Metspalu M et al. The genome-wide structure of the Jewish people. Nature 466(7303), 238-242 (2010).
36. Agrawal V, Huang N, Miller WL. Pharmacogenetics of P450 oxidoreductase: effect of sequence variants on activities of CYP1A2 and CYP2C19. Pharmacogenet. Genomics 18(7), 569-576 (2008).
37. Gomes LG, Huang N, Agrawal V, Mendonca BB, Bachega TA, Miller WL. The common P450 oxidoreductase variant A503V is not a modifier gene for 21-hydroxylase deficiency. J. Clin. Endocrinol. Metab. 93(7), 2913-2916 (2008). (Pubitemid 352008571)
38. Agrawal V, Choi JH, Giacomini KM, Miller WL. Substrate-specific modulation of CYP3A4 activity by genetic variants of cytochrome P450 oxidoreductase. Pharmacogenet. Genomics 20(10), 611-618 (2010).
39. Sandee D, Morrissey K, Agrawal V et al. Effects of genetic variants of human P450 oxidoreductase on catalysis by CYP2D6 in vitro. Pharmacogenet. Genomics 20(11), 677-686 (2010).
40. Sahakitrungruang T, Huang N, Tee MK et al. Clinical, genetic, and enzymatic characterization of P450 oxidoreductase deficiency in four patients. J. Clin. Endocrinol. Metab. 94(12), 4992-5000 (2009).
41. Fluck CE, Mullis PE, Pandey AV. Reduction in hepatic drug metabolizing CYP3A4 activities caused by P450 oxidoreductase mutations identified in patients with disordered steroid metabolism. Biochem. Biophys. Res. Commun. 401(1), 149-153 (2010).
42. Mast N, Liao WL, Pikuleva IA, Turko IV. Combined use of mass spectrometry and heterologous expression for identification of membrane-interacting peptides in cytochrome P450 46A1 and NADPHcytochrome P450 oxidoreductase. Arch. Biochem. Biophys. 483(1), 81-89 (2009).
43. Nicolo C, Fluck CE, Mullis PE, Pandey AV. Restoration of mutant cytochrome P450 reductase activity by external flavin. Mol. Cell. Endocrinol. 321(2), 245-252 (2010).
44. Soneda S, Yazawa T, Fukami M et al. Proximal promoter of the cytochrome P450 oxidoreductase gene: identification of microdeletions involving the untranslated exon 1 and critical function of the SP1 binding sites. J. Clin. Endocrinol. Metab. 96(11), E1881-E1887 (2011).
45. Tee MK, Huang N, Damm I, Miller WL. Transcriptional regulation of the human P450 oxidoreductase gene: hormonal regulation and influence of promoter polymorphisms. Mol. Endocrinol. 25(5), 715-731 (2011).
46. Scott RR, Miller WL. Genetic and clinical features of P450 oxidoreductase deficiency. Horm. Res. 69(5), 266-275 (2008). (Pubitemid 351693906)
47. Dhir V, Ivison HE, Krone N et al. Differential inhibition of CYP17A1 and CYP21A2 activities by the P450 oxidoreductase mutant A287P. Mol. Endocrinol. 21(8), 1958-1968 (2007). (Pubitemid 47173803)
48. Marohnic CC, Panda SP, Martasek P, Masters BS. Diminished FAD binding in the Y459H and V492E Antley-Bixler syndrome mutants of human cytochrome P450 reductase. J. Biol. Chem. 281(47), 35975-35982 (2006). (Pubitemid 46041329)
49. Marohnic C, Panda SP, McCammon K, Rueff J, Masters BS, Kranendonk M. Human cytochrome P450 oxidoreductase deficiency caused by the Y181D mutation: molecular consequences and rescue of defect. Drug Metab. Dispos. 38(2), 332-340 (2010).
50. Oneda B, Crettol S, Sirot EJ, Bochud M, Ansermot N, Eap CB. The P450 oxidoreductase genotype is associated with CYP3A activity in vivo as measured by the midazolam phenotyping test. Pharmacogenet. Genomics 19(11), 877-883 (2009).
51. Patki KC, Von Moltke LL, Greenblatt DJ. In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes P450: role of CYP3A4 and CYP3A5. Drug Metab. Dispos. 31(7), 938-944 (2003). (Pubitemid 36759065)
52. De Jonge H, Metalidis C, Naesens M, Lambrechts D, Kuypers DR. The P450 oxidoreductase *28 SNP is associated with low initial tacrolimus exposure and increased dose requirements in CYP3A5-expressing renal recipients. Pharmacogenomics 12(9), 1281-1291 (2011).
53. Tomalik-Scharte D, Maiter D, Kirchheiner J, Ivison HE, Fuhr U, Arlt W. Impaired hepatic drug and steroid metabolism in congenital adrenal hyperplasia due to P450 oxidoreductase deficiency. Eur. J. Endocrinol. 163(6), 919-924 (2010).
54. Moutinho D, Marohnic CC, Panda SP, Rueff J, Masters BS, Kranendonk M. Altered human CYP3A4 activity caused by Antley-Bixler syndrome-related variants of NADPHcytochrome P450 oxidoreductase measured in a robust in vitro system. Drug Metab. Dispos. doi:10.1124/dmd.111.042820 (2012) (Epub ahead of print).